Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Orchestra BioMed Holdings (OBIO) Shares Outstanding (Weighted Average) (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Shares Outstanding (Weighted Average) for 4 consecutive years, with $9.3 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 364.73% to $9.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.3 million through Dec 2025, up 364.73% year-over-year, with the annual reading at $9.3 million for FY2025, 364.73% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $9.3 million at Orchestra BioMed Holdings, roughly flat from $9.3 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $32.6 million in Q3 2023, with the low at $507841.0 in Q1 2025.
  • Average Shares Outstanding (Weighted Average) over 4 years is $6.4 million, with a median of $1.9 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) surged 2366.91% in 2023, then tumbled 94.03% in 2024.
  • Over 4 years, Shares Outstanding (Weighted Average) stood at $1.3 million in 2022, then surged by 46.6% to $1.9 million in 2023, then grew by 2.69% to $2.0 million in 2024, then soared by 364.73% to $9.3 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $9.3 million, $9.3 million, and $750000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.